Insitro Raises $400M Series C

Machine learning drug discovery company using data-driven approach to identify disease targets and develop therapeutics

Key Highlights

Funding Amount: $400M Series C
Valuation: $2.2B
Headquarters: South San Francisco, CA
Founded: 2018
Employees: 200-350
Total Raised: $743M

About the Funding Round

Insitro has successfully closed $400M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

ARCH Venture Partners
Foresite Capital
Canada Pension Plan

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Insitro achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Insitro's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2018 and headquartered in South San Francisco, CA, Insitro has established itself as an innovative player in the biotech space. With 200-350 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Insitro plans to:

Accelerate product development and innovation
Expand into new markets and geographies
Grow the team across engineering, sales, and operations
Strengthen partnerships with key industry players
Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Insitro's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.

For more information about Insitro, visit their website or contact their press office.